STCube to Hold Online Corporate Presentation on the 27th

[Asia Economy Reporter Hyungsoo Park] STCube, a company developing new immune checkpoint inhibitor drugs, announced on the 26th that it will hold an online investor relations (IR) meeting for analysts and institutional investors on the 27th.

Dr. Stephan Yoo, who oversees the research and development of the innovative new drug ‘hSTC810,’ will conduct the session via WebEX online video conference.

The innovative new drug hSTC810 being developed by STCube is an immune checkpoint inhibitor candidate targeting the ‘BTN1A1’ protein. BTN1A1 protein is an immune checkpoint protein first discovered by STCube and has a mutually exclusive expression characteristic with ‘PD-L1,’ which is used as a biomarker for existing immune checkpoint inhibitors. The hSTC810 antibody is intended for use in patients who are non-responsive to PD-1·PD-L1 therapies.

STCube recently presented two research results on hSTC810 at the American Association for Cancer Research (AACR) annual meeting. Clinical Phase 1 has begun recently with patient administration. Through the clinical trial, preliminary efficacy of hSTC810 monotherapy will be confirmed, and the maximum tolerated dose and maximum administered dose will be determined.

An STCube official stated, "We have signed confidentiality agreements (CDA) with multiple multinational pharmaceutical companies and are conducting meetings for technology transfer," adding, "Our goal is to achieve technology transfer based on the interim results of the hSTC810 Phase 1 clinical trial and turn profitable."